Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Neoplasms 1Constipation 1

Interventions

tegaserod 3naloxegol 3Radiotherapy 3Cisplatin 3Surveys and Questionnaires 2Radiation 2Lidocaine 2prucalopride 1pegfilgrastim 1oxycodone naloxone combination 1indole-3-carbinol 1hydrated silica gel-based toothpaste 1glucarpidase 1angiotensin I (1-7) 1alvimopan 1aluminum hydroxide, magnesium hydroxide, drug combination 1Vitamin D 1Transcutaneous Electric Nerve Stimulation 1Thyrotropin-Releasing Hormone 1Tablets 1Surgical Procedures, Operative 1Sennosides 1Selenomethionine 1Phenolphthalein 1Observation 1Nutrition Assessment 1Neck Dissection 1Methotrexate 1Methods 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × alvimopan × Other × Clear all
NCT00331045 2015-09-02

Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
21 enrolled
Other

Constipation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡